Treatment with immune-checkpoint blocking monoclonal antibody (mAb) is demonstrating a significant efficacy in different tumor types.Here, we discuss the impact of this promising approach in malignant mesothelioma (MM), a still dreadful disease in which medical treatment has been set on platinum based chemotherapy for decades with unsatisfactory results. (C) 2017 Elsevier Ltd. All rights reserved.
Calabro, L., Ceresoli, G.L., D'Incecco, A., Scherpereel, A., Aerts, J., Maio, M. (2017). Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences. CYTOKINE & GROWTH FACTOR REVIEWS, 36, 25-31 [10.1016/j.cytogfr.2017.07.003].
Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences
Maio M.
2017-01-01
Abstract
Treatment with immune-checkpoint blocking monoclonal antibody (mAb) is demonstrating a significant efficacy in different tumor types.Here, we discuss the impact of this promising approach in malignant mesothelioma (MM), a still dreadful disease in which medical treatment has been set on platinum based chemotherapy for decades with unsatisfactory results. (C) 2017 Elsevier Ltd. All rights reserved.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Immune-checkpoint-therapy-mesothelioma-Calabro-2017.pdf
non disponibili
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
519.91 kB
Formato
Adobe PDF
|
519.91 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1089976